<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684396</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-648_101</org_study_id>
    <secondary_id>U1111-1154-2329</secondary_id>
    <nct_id>NCT02684396</nct_id>
  </id_info>
  <brief_title>Phase 1, TAK-648, Single-Rising Dose Study</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo- Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single Oral TAK-648 Doses in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
      TAK-648 when administered as a single oral dose of TAK-648 solution at escalating dose levels
      in healthy participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a phase 1, randomized, double-blind, placebo-controlled, single-center, single-dose
      study in healthy participants. The study is the first TAK-648 study in humans and is designed
      to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a
      single dose of TAK-648 to healthy participants.

      The compound being tested in this study is TAK-648. TAK-648 is being tested to find a safe
      and well-tolerated single dose.

      This study measured how much of the study drug got into the blood stream and how long it took
      the body to get rid of it. Information about any side effects that may have occurred was also
      collected. This study was a randomized dose-rising study which means that the first group of
      research participants was assigned by chance to receive either the study drug or placebo.
      Placebo is a solution that looks like the study drug but has no active ingredient. The lowest
      dose of the study drug or placebo was given to the 1st group of participants (1st cohort) and
      a higher dose was given to the next group until all the doses of the study drug were tested.
      TAK-648 was dosed in 5 sequential cohorts with escalating doses from the lowest dose given in
      Cohort 1 to higher doses given in the subsequent cohort. Doses could be adjusted based on
      available safety, tolerability, and pharmacokinetic (PK) data.

      Approximately 40 healthy male and female participants were planned for enrollment with 8
      subjects planned (6 randomized to TAK-648 and 2 randomized to placebo) for each cohort. The
      study included 5 cohorts.

      This single-center trial was conducted in the United States. The overall time to participate
      in this study was up to 45 days. Participants made multiple visits to the clinic, including
      one 5-day period of confinement to the clinic. All participants were contacted by telephone
      14 days after the last dose of study drug and on Day 84 (+/-2 days) for a follow-up
      assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>Day 1 to Day 14</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet the Markedly Abnormal Criteria, for Safety Laboratory Tests at Least Once Post-dose</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>The percentage of participants with any markedly abnormal standard safety laboratory values (chemistry, hematology and urinalysis) collected throughout study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Signs Measurements at Least Once Post-dose</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Vital signs will include body temperature (oral), sitting blood pressure (after the participant has rested for at least 5 minutes), respiration rate and pulse (bpm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One Occurrence of Severe Hypoglycemia Post-dose</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Severe hypoglycemia is defined as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-648</measure>
    <time_frame>Multiple time-points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-648</measure>
    <time_frame>Multiple time-points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-648</measure>
    <time_frame>Multiple time-points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-648</measure>
    <time_frame>Multiple time-points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1: TAK-648 0.05 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: TAK-648 0.15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: TAK-648 0.35 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: TAK-648 0.7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: TAK-648 0.85 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1-5: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-648 placebo-matching solution, orally, once on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-648</intervention_name>
    <description>TAK-648 Solution</description>
    <arm_group_label>Cohort 1: TAK-648 0.05 mg</arm_group_label>
    <arm_group_label>Cohort 2: TAK-648 0.15 mg</arm_group_label>
    <arm_group_label>Cohort 3: TAK-648 0.35 mg</arm_group_label>
    <arm_group_label>Cohort 4: TAK-648 0.7 mg</arm_group_label>
    <arm_group_label>Cohort 5: TAK-648 0.85 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-648 Placebo</intervention_name>
    <description>TAK-648 placebo-matching solution</description>
    <arm_group_label>Cohort 1-5: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy adult male or non-pregnant, non-lactating female.

          2. Is aged 18 to 55 years, inclusive.

          3. Weighs at least 55 kg (121 lbs) and has a body mass index (BMI) between 18.0 and 30.0
             kg/m^2, inclusive.

          4. Has a systolic blood pressure &gt;90 and ≤150 mm Hg and a diastolic blood pressure of &gt;60
             and ≤90 mm Hg at Screening and at Check-in (Day -2).

          5. Has a calculated creatinine clearance &gt;60 mL/min at Screening and Check-in (Day -2).

        Exclusion Criteria:

          1. Has a known hypersensitivity to any component of the formulation of TAK-648,
             phosphodiesterase inhibitors or Listerine strips.

          2. Has significant medical histories or currently uncontrolled clinical conditions, which
             may not be safe for participant to participate in the study, may impact the
             participant's ability to participate in the study; may influence absorption of the
             study drug, or may potentially confound the study results.

          3. Has a history of persistent, chronic or intermittent nausea, vomiting, or diarrhea or
             had a current or recent (within 6 months) gastrointestinal disease that would
             influence the absorption of drugs

          4. Has a diagnosis of major depression, bipolar disorder, or anxiety disorders or
             received any medication to treat any psychological disorders within 1 year prior to
             Screening.

          5. Has abnormal laboratory values that suggest a clinically significant underlying
             disease or has the following laboratory abnormalities: alanine aminotransferase (ALT)
             and/or aspartate aminotransferase (AST) &gt;2.5 times the upper limits of normal.

          6. Use of any excluded medications, supplement, or food product outlined in the protocol.

          7. Use of new medications during the course of the study including through the Follow-up
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <results_first_submitted>June 2, 2016</results_first_submitted>
  <results_first_submitted_qc>June 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2016</results_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United States from 19 August 2014 to 08 July 2015.</recruitment_details>
      <pre_assignment_details>Healthy Volunteers were enrolled in 1 of 6 treatment groups, once a day placebo, TAK-648 0.05 mg, 0.15 mg, 0.35 mg, 0.7 mg or 0.85 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: TAK-648 0.05 mg</title>
          <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: TAK-648 0.15 mg</title>
          <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: TAK-648 0.35 mg</title>
          <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4: TAK-648 0.7 mg</title>
          <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5: TAK-648 0.85 mg</title>
          <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 1-5: Placebo</title>
          <description>TAK-648 placebo-matching solution, orally, once on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: TAK-648 0.05 mg</title>
          <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: TAK-648 0.15 mg</title>
          <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3: TAK-648 0.35 mg</title>
          <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4: TAK-648 0.7 mg</title>
          <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5: TAK-648 0.85 mg</title>
          <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 1-5: Placebo</title>
          <description>TAK-648 placebo-matching solution, orally, once on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" spread="13.21"/>
                    <measurement group_id="B2" value="32.5" spread="11.08"/>
                    <measurement group_id="B3" value="37.5" spread="9.07"/>
                    <measurement group_id="B4" value="37.0" spread="9.78"/>
                    <measurement group_id="B5" value="45.0" spread="11.51"/>
                    <measurement group_id="B6" value="36.2" spread="11.10"/>
                    <measurement group_id="B7" value="37.5" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic and Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177.2" spread="9.24"/>
                    <measurement group_id="B2" value="169.0" spread="8.58"/>
                    <measurement group_id="B3" value="172.2" spread="11.82"/>
                    <measurement group_id="B4" value="163.3" spread="8.21"/>
                    <measurement group_id="B5" value="170.6" spread="12.26"/>
                    <measurement group_id="B6" value="176.4" spread="8.46"/>
                    <measurement group_id="B7" value="172.0" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.1" spread="12.39"/>
                    <measurement group_id="B2" value="70.0" spread="9.32"/>
                    <measurement group_id="B3" value="75.6" spread="12.86"/>
                    <measurement group_id="B4" value="67.1" spread="4.36"/>
                    <measurement group_id="B5" value="76.1" spread="12.79"/>
                    <measurement group_id="B6" value="77.7" spread="14.33"/>
                    <measurement group_id="B7" value="74.1" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="3.60"/>
                    <measurement group_id="B2" value="24.5" spread="2.42"/>
                    <measurement group_id="B3" value="25.4" spread="2.37"/>
                    <measurement group_id="B4" value="25.3" spread="2.73"/>
                    <measurement group_id="B5" value="26.0" spread="2.26"/>
                    <measurement group_id="B6" value="24.8" spread="3.03"/>
                    <measurement group_id="B7" value="25.0" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hip Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.33" spread="6.683"/>
                    <measurement group_id="B2" value="96.33" spread="3.141"/>
                    <measurement group_id="B3" value="98.50" spread="8.385"/>
                    <measurement group_id="B4" value="102.83" spread="4.956"/>
                    <measurement group_id="B5" value="102.20" spread="4.207"/>
                    <measurement group_id="B6" value="98.63" spread="7.121"/>
                    <measurement group_id="B7" value="99.47" spread="6.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.83" spread="9.174"/>
                    <measurement group_id="B2" value="82.50" spread="6.863"/>
                    <measurement group_id="B3" value="90.00" spread="5.762"/>
                    <measurement group_id="B4" value="86.17" spread="7.548"/>
                    <measurement group_id="B5" value="95.00" spread="3.391"/>
                    <measurement group_id="B6" value="88.06" spread="10.865"/>
                    <measurement group_id="B7" value="87.91" spread="8.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist to Hip Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.87" spread="0.037"/>
                    <measurement group_id="B2" value="0.86" spread="0.061"/>
                    <measurement group_id="B3" value="0.92" spread="0.038"/>
                    <measurement group_id="B4" value="0.84" spread="0.074"/>
                    <measurement group_id="B5" value="0.93" spread="0.034"/>
                    <measurement group_id="B6" value="0.89" spread="0.069"/>
                    <measurement group_id="B7" value="0.88" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event (TEAE)</title>
        <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>Day 1 to Day 14</time_frame>
        <population>Safety Analysis Set included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-648 0.05 mg</title>
            <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-648 0.15 mg</title>
            <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-648 0.35 mg</title>
            <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-648 0.7 mg</title>
            <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-648 0.85 mg</title>
            <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1-5: Placebo</title>
            <description>TAK-648 placebo-matching solution, orally, once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event (TEAE)</title>
          <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety Analysis Set included all randomized participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="20.0"/>
                    <measurement group_id="O6" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria, for Safety Laboratory Tests at Least Once Post-dose</title>
        <description>The percentage of participants with any markedly abnormal standard safety laboratory values (chemistry, hematology and urinalysis) collected throughout study.</description>
        <time_frame>Day 1 to Day 4</time_frame>
        <population>Safety Analysis Set included all enrolled participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-648 0.05 mg</title>
            <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-648 0.15 mg</title>
            <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-648 0.35 mg</title>
            <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-648 0.7 mg</title>
            <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-648 0.85 mg</title>
            <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1-5: Placebo</title>
            <description>TAK-648 placebo-matching solution, orally, once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria, for Safety Laboratory Tests at Least Once Post-dose</title>
          <description>The percentage of participants with any markedly abnormal standard safety laboratory values (chemistry, hematology and urinalysis) collected throughout study.</description>
          <population>Safety Analysis Set included all enrolled participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chemistry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinalysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Signs Measurements at Least Once Post-dose</title>
        <description>Vital signs will include body temperature (oral), sitting blood pressure (after the participant has rested for at least 5 minutes), respiration rate and pulse (bpm).</description>
        <time_frame>Day 1 to Day 4</time_frame>
        <population>Safety Analysis Set included all enrolled participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-648 0.05 mg</title>
            <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-648 0.15 mg</title>
            <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-648 0.35 mg</title>
            <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-648 0.7 mg</title>
            <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-648 0.85 mg</title>
            <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1-5: Placebo</title>
            <description>TAK-648 placebo-matching solution, orally, once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Signs Measurements at Least Once Post-dose</title>
          <description>Vital signs will include body temperature (oral), sitting blood pressure (after the participant has rested for at least 5 minutes), respiration rate and pulse (bpm).</description>
          <population>Safety Analysis Set included all enrolled participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; Lower Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="20.0"/>
                    <measurement group_id="O6" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; Upper Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least One Occurrence of Severe Hypoglycemia Post-dose</title>
        <description>Severe hypoglycemia is defined as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.</description>
        <time_frame>Day 1 to Day 4</time_frame>
        <population>Safety Analysis Set included all enrolled participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-648 0.05 mg</title>
            <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-648 0.15 mg</title>
            <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-648 0.35 mg</title>
            <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-648 0.7 mg</title>
            <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-648 0.85 mg</title>
            <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 1-5: Placebo</title>
            <description>TAK-648 placebo-matching solution, orally, once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Occurrence of Severe Hypoglycemia Post-dose</title>
          <description>Severe hypoglycemia is defined as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.</description>
          <population>Safety Analysis Set included all enrolled participants who received study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-648</title>
        <time_frame>Multiple time-points (up to 72 hours) post-dose</time_frame>
        <population>PK Analysis Set included all enrolled participants who had at least 1 measureable plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-648 0.05 mg</title>
            <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-648 0.15 mg</title>
            <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-648 0.35 mg</title>
            <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-648 0.7 mg</title>
            <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-648 0.85 mg</title>
            <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-648</title>
          <population>PK Analysis Set included all enrolled participants who had at least 1 measureable plasma concentration.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.619" spread="0.2461"/>
                    <measurement group_id="O2" value="2.330" spread="0.8022"/>
                    <measurement group_id="O3" value="3.997" spread="1.5958"/>
                    <measurement group_id="O4" value="11.845" spread="2.6415"/>
                    <measurement group_id="O5" value="11.712" spread="6.2166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-648</title>
        <time_frame>Multiple time-points (up to 72 hours) post-dose</time_frame>
        <population>PK Analysis Set included all enrolled participants who had at least 1 measureable plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-648 0.05 mg</title>
            <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-648 0.15 mg</title>
            <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-648 0.35 mg</title>
            <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-648 0.7 mg</title>
            <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-648 0.85 mg</title>
            <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-648</title>
          <population>PK Analysis Set included all enrolled participants who had at least 1 measureable plasma concentration.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.500" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O3" value="1.000" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O4" value="1.000" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O5" value="1.000" lower_limit="1.00" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-648</title>
        <time_frame>Multiple time-points (up to 72 hours) post-dose</time_frame>
        <population>PK Analysis Set included all enrolled participants who had at least 1 measureable plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-648 0.05 mg</title>
            <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-648 0.15 mg</title>
            <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-648 0.35 mg</title>
            <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-648 0.7 mg</title>
            <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-648 0.85 mg</title>
            <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-648</title>
          <population>PK Analysis Set included all enrolled participants who had at least 1 measureable plasma concentration.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.452" spread="2.2891"/>
                    <measurement group_id="O2" value="16.614" spread="4.6927"/>
                    <measurement group_id="O3" value="27.927" spread="9.5790"/>
                    <measurement group_id="O4" value="75.280" spread="25.2406"/>
                    <measurement group_id="O5" value="92.661" spread="30.0958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-648</title>
        <time_frame>Multiple time-points (up to 72 hours) post-dose</time_frame>
        <population>PK Analysis Set included all enrolled participants who had at least 1 measureable plasma concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: TAK-648 0.05 mg</title>
            <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: TAK-648 0.15 mg</title>
            <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: TAK-648 0.35 mg</title>
            <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: TAK-648 0.7 mg</title>
            <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: TAK-648 0.85 mg</title>
            <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-648</title>
          <population>PK Analysis Set included all enrolled participants who had at least 1 measureable plasma concentration.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.585" spread="2.2743"/>
                    <measurement group_id="O2" value="16.813" spread="4.6918"/>
                    <measurement group_id="O3" value="28.266" spread="9.5872"/>
                    <measurement group_id="O4" value="75.774" spread="25.3966"/>
                    <measurement group_id="O5" value="93.840" spread="30.8531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 Days</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: TAK-648 0.05 mg</title>
          <description>TAK-648 0.05 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: TAK-648 0.15 mg</title>
          <description>TAK-648 0.15 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3: TAK-648 0.35 mg</title>
          <description>TAK-648 0.35 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4: TAK-648 0.7 mg</title>
          <description>TAK-648 0.7 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5: TAK-648 0.85 mg</title>
          <description>TAK-648 0.85 mg, solution, orally, once on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 1-5: Placebo</title>
          <description>TAK-648 placebo-matching solution, orally, once on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure orthostatic abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood pressure orthostatic decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

